Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine.
Bilal MalikAtefeh KalantaryKamal RikabiArvind KunadiPublished in: BMJ case reports (2021)
As with past illnesses, an approach has been taken to vaccinate the population and halt the spread of COVID-19. On 13 April 2021, the US Food and Drug Administration called for a halt in the administration of the Johnson & Johnson (J&J) COVID-19 vaccine due to reports of thrombosis and thrombocytopenia being associated with vaccination. We present the case of a 43-year-old woman with a history of dyslipidaemia, depression, gastro-oesophageal reflux disease and obesity presenting with dyspnoea, headache and light headedness of 3 days' duration. Ten days prior, she had received the J&J COVID-19 vaccine. She was found to have thrombocytopenia, elevated D-dimers, pulmonary emboli and presented 1 day after discharge with an arterial clot despite being on apixaban. Six other US-based cases of venous thrombotic events are being reviewed at present. Patients should be informed of the possibility of such events to provide informed consent.
Keyphrases
- coronavirus disease
- pulmonary embolism
- sars cov
- inferior vena cava
- ejection fraction
- metabolic syndrome
- drug administration
- respiratory syndrome coronavirus
- insulin resistance
- depressive symptoms
- emergency department
- weight loss
- pulmonary hypertension
- venous thromboembolism
- prognostic factors
- atrial fibrillation
- patient reported outcomes
- body mass index
- risk assessment
- subarachnoid hemorrhage
- weight gain
- high fat diet induced
- gastroesophageal reflux disease